

Summary Product Characteristic for Pharmaceutical Product

1. Name of the medicinal product

Allercrom Eye Drops

2. Qualitative and quantitative composition

Each ml of eye drops contains 20 mg sodium cromoglicate (2.0% w/v), (one drop contains 0.7mg sodium cromoglicate).

Excipients with known effect:

0.1 mg benzalkonium chloride

For the full list of excipients, see section 6.1

3. Pharmaceutical form

Clear colourless solution free from visible particulate matter

4. Clinical particulars

4.1 Therapeutic indications

For the prophylaxis and symptomatic treatment of acute allergic conjunctivitis, chronic allergic conjunctivitis and vernal keratoconjunctivitis.

4.2 Posology and method of administration

Ocular use

Adults and Children:

One or two drops to be administered into each eye four times daily or as indicated by the doctor.

Elderly

There is no evidence to suggest that dosage alteration is required for elderly patients.

4.3 Contraindications

Hypersensitivity to the active substance or to any of the excipients listed in section 6.1.

4.4 Special warnings and precautions for use

Discard any remaining contents four weeks after opening the bottle.

This medicine contains Benzalkonium Chloride

As with other ophthalmic solutions containing Benzalkonium chloride, soft contact lenses should not be worn during treatment period.

From the limited data available, there is no difference in the adverse event profile in children compared to adults.

Generally, however, eyes in children show a stronger reaction for a given stimulus than the adult eye. Irritation may have an effect on treatment adherence in children.

Benzalkonium chloride has been reported to cause eye irritation, symptoms of dry eyes and may affect the tear film and corneal surface. Should be used with caution in dry eye patients and in patients where the cornea may be compromised.

Patients should be monitored in case of prolonged use

4.5 Interaction with other medicinal products and other forms of interaction

No interaction studies have been performed.

4.6 Fertility, pregnancy and lactation

Fertility:

It is not known whether sodium cromoglicate has any effect on fertility.

Pregnancy:

As with all medication, caution should be exercised especially during the first trimester of pregnancy. Cumulative experience with sodium cromoglicate suggests that it has no adverse effects on foetal development. It should be used in pregnancy only where there is a clear need.

Lactation:

It is not known whether sodium cromoglicate is excreted in human breast milk but, on the basis of its physicochemical properties, this is considered unlikely. There is no information to suggest the use of sodium cromoglicate has any undesirable effects on the baby.

4.7 Effects on ability to drive and use machines

Sodium cromoglicate has a minor influence on the ability to drive and use machines.

As with all eye drops, instillation of these eye drops may cause a transient blurring of vision. Patients are advised not to drive or operate machinery if affected, until their vision returns to normal.

4.8 Undesirable effects

Eye disorders

Transient stinging and burning may occur after instillation. Other symptoms of local irritation have been reported rarely.

Reporting of suspected adverse reactions: Healthcare professionals are asked to report any suspected adverse reactions via pharmacy and poisons board, Pharmacovigilance Electronic Reporting System (PvERS) <https://pv.pharmacyboardkenya.org>

4.9 Overdose

Overdosage is very unlikely. In the event of accidental ingestion, symptomatic treatment is recommended.

5. Pharmacological properties

5.1 pharmacodynamic properties

Pharmacotherapeutic group: Ophthalmologicals; Other antiallergics, ATC code: S01GX01

The solution exerts its effect locally in the eye.

In vitro and *in vivo* animal studies have shown that sodium cromoglicate inhibits the degranulation of sensitised mast cells which occurs after exposure to specific antigens. sodium cromoglicate acts by inhibiting the release of histamine and various membrane derived mediators from the mast cell.

Sodium cromoglicate has demonstrated the activity *in vitro* to inhibit the degranulation of non-sensitised rat mast cells by phospholipase A and subsequent release of chemical mediators. sodium cromoglicate did not inhibit the enzymatic activity of released phospholipase A on its specific substrate.

Sodium cromoglicate has no intrinsic vasoconstrictor or antihistamine activity.

5.2 Pharmacokinetic properties

Sodium cromoglicate is poorly absorbed. When multiple doses of sodium cromoglicate ophthalmic solution are instilled into normal rabbit eyes, less than 0.07% of the administered dose of sodium cromoglicate is absorbed into the systemic circulation (presumably by way of the eye, nasal passages, buccal cavity and gastrointestinal tract). Trace amounts (less than 0.01%) of the sodium cromoglicate does penetrate into the aqueous humour and clearance from this chamber is virtually complete within 24 hours after treatment is stopped.

In normal volunteers, analysis of drug excretion indicates that approximately 0.03% of sodium cromoglicate is absorbed following administration to the eye.

5.3 Preclinical safety data

None stated.

6. Pharmaceutical particulars

6.1 List of excipients

Disodium Edetate
Sodium Chloride
Benzalkonium Chloride
Polysorbate 80
Water For Injection

6.2 Incompatibilities

Not applicable.

6.3 Shelf life

2 years

6.4 Special precautions for storage

Store below 30°C. Protect from sunlight and moisture. Keep out of reach of children.

6.5 Nature and contents of container

10 ml solution filled in 10 ml labeled LDPE vial with HIPS spike cap packed in a carton.

6.6 Special precautions for disposal and other handling

Any unused medicinal product or waste material should be disposed in accordance with local requirements.

7. Marketing authorisation holder and manufacturing site addresses

Marketing authorisation holder

FDC Limited B-8,
MIDC Industrial Area, Waluj , Aurangabad – 431136
Maharashtra , India
Telephone Number : 0240-2554407/4967/4963
Fax Number : 0240-2554299

Manufacturing Site Address

FDC Limited B-8,
MIDC Industrial Area, Waluj , Aurangabad – 431136
Maharashtra , India
Telephone Number : 0240-2554407/4967/4963
Fax Number : 0240-2554299

8. Marketing authorisation number(s)

H2024/CTD9194/15817

9. Date of first authorisation/renewal of the authorisation

Date of first authorization: 23-Feb-2024

10. Date of revision of the text

Nov-2024